Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mQFPD for mild-to-moderate COVID-19
NCT04939415Phase 1Completed
- Sponsor
- University of California, San Diego
- Start
- Jul 2021
- Primary completion
- Jan 2022
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing mQFPD with Placebo (2 arms). Primary endpoints: Total Protein Normal to Abnormal Transition at 14 days, Albumin Normal to Abnormal Transition at 14 days and 10 more. Started Jul 2021; status: completed.
02
Drugs
modified Qing Fei Pai Du Tang
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04939415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939415.